HIV vaccines: new frontiers in vaccine development.
A human immunodeficiency virus (HIV) vaccine is the most promising and feasible strategy to prevent the events during acute infection that simultaneously set the course of the epidemic in the community and the course of the disease for the individual. Because safety concerns limit the use of live, attenuated HIV and inactivated HIV, a variety of alternate approaches is being investigated. Traditional antibody-mediated approaches using recombinant HIV envelope proteins have shown no efficacy in 2 phase III trials. Current HIV vaccine trials are focusing primarily on cytotoxic T lymphocyte-mediated products that use viral vectors, either alone or as boosts to DNA plasmids that contain viral genes. The most immunogenic of these products appear to be the recombinant adenovirus vector vaccines, 2 of which are now in advanced clinical development.
Duerr
Ann
A
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. aduerr@hvtn.org
Wasserheit
Judith N
JN
Corey
Lawrence
L
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000256:Adenoviridae / Q000276:immunology; D000818:Animals; D004279:DNA, Viral / Q000276:immunology; D004199:Disease Vectors; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans
D016915:AIDS Vaccines; D004279:DNA, Viral